Arbutus plans up to $230 million Dutch auction tender offer for its common shares
Arbutus Biopharma announced plans for a modified Dutch auction tender offer to buy back up to $230 million of its common shares, at $5.00 to $5.75 per share, funded from cash on hand. The offer has not yet commenced and is subject to exemptive relief, so its terms and completion are not assured, but it would return proceeds from the Moderna settlement to shareholders.
Key points
- Offer to repurchase up to $230 million of common shares at not less than $5.00 and not more than $5.75 per share, in cash
- Expected to commence on or about August 24, 2026, and expire on or about September 29, 2026, unless extended or terminated
- Funded through the company's cash on hand; commencement depends on obtaining exemptive relief under Canadian and US securities laws
- Follows the March 2026 Moderna settlement and a July 2026 initial payment under that settlement
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 21, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.